Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax alone or with zanubrutinib in Waldenström macroglobulinemia
2023-503235-18-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of sonrotoclax and zanubrutinib in Waldenström macroglobulinemia (WM) (4 cohorts), sponsored by BeOne Medicines. Primary endpoint: Major response rate. Planned start Jan 2024; status: authorised.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2023-503235-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503235-18-00.